ASCENTAGE PHARMA GROUP INTERNATIONAL

Ascentage Pharma Group International is a clinical-stage biotechnology company developing small-molecule therapies for oncology, chronic hepatitis B, and age-related diseases, primarily targeting the Chinese market. The company's pipeline includes multiple candidates in various development stages: HQP1351, a BCR-ABL inhibitor designed to treat BCR-ABL1 mutations including T315I; APG-2575, a Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; and APG-115, an MDM2-p53 inhibitor for solid tumors and hematological malignancies. Additional programs include APG-1252 for small-cell and non-small cell lung cancers, APG-1387 for advanced solid tumors and chronic hepatitis B infection, APG-2449 targeting multiple kinases, and APG-5918, a selective EED inhibitor.

The company operates through drug development and clinical trial operations as its core business activities. Ascentage also engages in venture capital investment, real estate rental, and science and technology promotion services. The company maintains collaboration relationships with biotechnology firms, pharmaceutical companies, and research institutions.

Based in Suzhou, China and incorporated in the Cayman Islands, Ascentage employs approximately 605 full-time staff. The company is listed on Nasdaq with a market capitalization of $2.3 billion as of the data provided.